The co-inactivation of LKB1 and KEAP1 cooperatively promotes metabolic reprogramming in KRAS-mutant tumor, and even in the presence of KEAP1 inactivation, LKB1 inactivation modulates NRF2 activity through increased ROS levels (104). The gene discussed is KRAS; the disease is neoplasm.